Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024

Documenti analoghi

• Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
  di: Nadine Ezard, et al.
  Pubblicazione: (2025)
• Trends in gamma‐hydroxybutyrate use, harms and treatment in Australia, 2013 to 2024
  di: Amy Peacock, et al.
  Pubblicazione: (2026)
• Contents and Time‐Course of Falsified Alprazolam Detections in New South Wales, Australia
  di: Janette L. Smith, et al.
  Pubblicazione: (2025)
• Substance Use and Sex Index version 2 (SUSI‐2): Validation of a brief questionnaire for the measurement of behaviours associated with transmission of blood borne viruses and sexually transmitted infections
  di: Brendan Clifford, et al.
  Pubblicazione: (2025)
• Trends in reported GHB‐related presentations to Sydney emergency departments between 2012 and 2021
  di: Oliver Harris, et al.
  Pubblicazione: (2024)